234 related articles for article (PubMed ID: 26076664)
1. Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas.
de Moll EH; Fu Y; Qian Y; Perkins SH; Wieder S; Gnjatic S; Remark R; Bernardo SG; Moskalenko M; Yao J; Ferringer T; Chang R; Chipuk J; Horst BA; Birge MB; Phelps RG; Saenger YM
Cancer Immunol Immunother; 2015 Sep; 64(9):1193-203. PubMed ID: 26076664
[TBL] [Abstract][Full Text] [Related]
2. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
[TBL] [Abstract][Full Text] [Related]
3. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
[TBL] [Abstract][Full Text] [Related]
4. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome.
Garg K; Maurer M; Griss J; Brüggen MC; Wolf IH; Wagner C; Willi N; Mertz KD; Wagner SN
Hum Pathol; 2016 Aug; 54():157-64. PubMed ID: 27107457
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating lymphocytes predict cutaneous melanoma survival.
Fortes C; Mastroeni S; Mannooranparampil TJ; Passarelli F; Zappalà A; Annessi G; Marino C; Caggiati A; Russo N; Michelozzi P
Melanoma Res; 2015 Aug; 25(4):306-11. PubMed ID: 25933208
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
[TBL] [Abstract][Full Text] [Related]
7. Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status.
Dabrosin N; Sloth Juul K; Bæhr Georgsen J; Andrup S; Schmidt H; Steiniche T; Heide Øllegaard T; Bønnelykke Behrndtz L
Melanoma Res; 2019 Feb; 29(1):30-37. PubMed ID: 30299387
[TBL] [Abstract][Full Text] [Related]
8. Decreased tumor-infiltrating lymphocytes in nodular melanomas compared with matched superficial spreading melanomas.
Lin RL; Wang TJ; Joyce CJ; Mihm MC; Murphy GF; Lian CG; Lin JY
Melanoma Res; 2016 Oct; 26(5):524-7. PubMed ID: 26974966
[TBL] [Abstract][Full Text] [Related]
9. Coexistence of regression and tumor infiltrating lymphocytes is associated with more favorable survival in melanoma.
Tas F; Erturk K
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2721-2729. PubMed ID: 33611652
[TBL] [Abstract][Full Text] [Related]
10. Plasma cells in primary melanoma. Prognostic significance and possible role of IgA.
Bosisio FM; Wilmott JS; Volders N; Mercier M; Wouters J; Stas M; Blokx WA; Massi D; Thompson JF; Scolyer RA; van Baren N; van den Oord JJ
Mod Pathol; 2016 Apr; 29(4):347-58. PubMed ID: 26867783
[TBL] [Abstract][Full Text] [Related]
11. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.
Miracco C; Mourmouras V; Biagioli M; Rubegni P; Mannucci S; Monciatti I; Cosci E; Tosi P; Luzi P
Oncol Rep; 2007 Nov; 18(5):1115-22. PubMed ID: 17914561
[TBL] [Abstract][Full Text] [Related]
12. Assessing the Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Melanoma Using Pathologic Features Identified by Natural Language Processing.
Yang J; Lian JW; Chin YH; Wang L; Lian A; Murphy GF; Zhou L
JAMA Netw Open; 2021 Sep; 4(9):e2126337. PubMed ID: 34550383
[TBL] [Abstract][Full Text] [Related]
13. Local immune response predicts survival in patients with thick (t4) melanomas.
Cintolo JA; Gimotty P; Blair A; Guerry D; Elder DE; Hammond R; Elenitsas R; Xu X; Fraker D; Schuchter LM; Czerniecki BJ; Karakousis G
Ann Surg Oncol; 2013 Oct; 20(11):3610-7. PubMed ID: 23838911
[TBL] [Abstract][Full Text] [Related]
14. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.
van Houdt IS; Sluijter BJ; Moesbergen LM; Vos WM; de Gruijl TD; Molenkamp BG; van den Eertwegh AJ; Hooijberg E; van Leeuwen PA; Meijer CJ; Oudejans JJ
Int J Cancer; 2008 Aug; 123(3):609-15. PubMed ID: 18498132
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating lymphocyte response in cutaneous melanoma in the elderly predicts clinical outcomes.
Grotz TE; Vaince F; Hieken TJ
Melanoma Res; 2013 Apr; 23(2):132-7. PubMed ID: 23344159
[TBL] [Abstract][Full Text] [Related]
16. Primary tumour ulceration in cutaneous melanoma: its role on TNM stages.
Tas F; Erturk K
Jpn J Clin Oncol; 2021 Feb; 51(2):192-198. PubMed ID: 33159197
[TBL] [Abstract][Full Text] [Related]
17. Tumor Infiltrating Lymphocytes (TILs) May be Only an Independent Predictor of Nodal Involvement but not for Recurrence and Survival in Cutaneous Melanoma Patients.
Tas F; Erturk K
Cancer Invest; 2017 Sep; 35(8):501-505. PubMed ID: 28799813
[TBL] [Abstract][Full Text] [Related]
18. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
[TBL] [Abstract][Full Text] [Related]
19. Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas.
Koelblinger P; Emberger M; Drach M; Cheng PF; Lang R; Levesque MP; Bauer JW; Dummer R
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):667-675. PubMed ID: 30357969
[TBL] [Abstract][Full Text] [Related]
20. FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor.
Leslie C; Bowyer SE; White A; Grieu-Iacopetta F; Trevenen M; Iacopetta B; Amanuel B; Millward M
Pathology; 2015 Oct; 47(6):557-63. PubMed ID: 26308130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
